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Dispatchessynaptic weight, the location of synapses
with excitatory versus inhibitory effects in
the post-synaptic neuron, and the ability
for computation within the dendritic tree
of a neuron. Finally, simultaneous
intracellular or extra cellular recordings
from neurons in different modules could
help to evaluate the link between network
structure and function.
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MAGE-A proteins are testis-specific E3 ubiquitin ligase components whose expression is upregulated in
many cancers. MAGE-A3 and -A6 act as oncogenes and recent work now shows that they degrade the
central metabolic regulator AMPK, providing a novel mechanism for rewiring cancer metabolism.AMP-activated protein kinase (AMPK) is a
serine/threonine kinase that is activated
under conditions of low cellular energy,
such as those that accompany loss of
nutrients, particularly glucose and
oxygen. AMPK plays a highly conserved
role as an energy sensor and acts
to restore metabolic homeostasis on
a cellular and ultimately organismallevel by downregulating anabolic
biosynthetic ATP-consuming processes,
like protein and lipid biosynthesis,
and upregulating catabolic ATP-restoring
processes, like autophagy and fatty
acid oxidation. As such, AMPK is one
of the central metabolic regulators
that dominantly impacts overall
metabolic state across most cell typesand tissues studied to date in all
eukaryotes [1].
AMPK has also been linked with
cancer, being one of the best-studied
substrates of the LKB1 tumor suppressor,
which is inactivated in 25% of lung
adenocarcinomas and is the single gene
responsible for the inherited cancer
predisposition disorder Peutz-Jeghers
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Dispatchessyndrome [2]. There are two catalytic
AMPK genes in mammals, AMPKa1 and
AMPKa2, and LKB1 directly
phosphorylates and stimulates the
kinase activity of both. Thus, most
tumors and cell types in which LKB1
is mutated can no longer activate
AMPK in response to metabolic stress.
The role of AMPK in maintaining
metabolic homeostasis also accounts
for its requirement for cell survival after
a number of metabolic insults, including
tumor cells in different contexts [3].
This potential dual nature of the role
of AMPK in cancer has been noted
in many cellular and xenograft
contexts but remains to be critically
analyzed in autochthonous mouse
models of cancer.
While phosphorylation of the activation
loop threonine of AMPK (Thr172 in
human AMPKa2) has been thoroughly
studied as the central post-translational
modification required for AMPK
activation, less is known about how
other post-translational modifications
of AMPK subunits modulate AMPK
function. In the past decade,
evidence for inhibitory phosphorylation
at the carboxyl terminus of AMPKa
proteins has been accumulating
and AMPK has been reported to be
acetylated and glycosylated in
response to various nutrient-excess
conditions [4]. In contrast, much
less attention has been paid to
the regulated degradation of AMPK,
which is surprising given how
the central nodes of signaling
pathways — such as AMPK — are
often regulated by all possible
mechanistic avenues.
Coming from an entirely distinct focus
of trying to decode the targets for E3
ubiquitin ligase complexes, Potts and
colleagues [5] now report the
identification of the genes MAGE
(melanoma antigen genes)-A3
and MAGE-A6 as being critical
regulators of AMPK turnover. The
remarkable feature of MAGE-A3/6 is
that RNA sequencing reveals that
their normal tissue expression is
exquisitely restricted to the testis in
mice and humans. However, as
their name implies, these genes are
highly expressed in the majority of
melanomas analyzed, as well as in
lung squamous and adenocarcinomas,Cand in head and neck and colorectal
tumors amongst others. Knockdown
of these two highly related genes
resulted in loss of cell viability in a
number of cancer cell lines bearing their
expression [5]. Conversely, enforced
overexpression of MAGE-A6 in cancer
cells lacking MAGE-A3/6 expression
or in immortalized but non-transformed
NIH3T3 cells or human colonic epithelial
cells was sufficient to promote foci
formation and anchorage-independent
growth on a scale similar to or
greater than that induced by classic
oncogenes, e.g. an activated KrasV12
mutant [5].
Previously, Potts and colleagues
discovered that the MAGE family of
proteins acts to scaffold members of
the large TRIM family of E3 ubiquitin
ligases to their substrates [6]. In particular,
the testis-specific MAGE proteins
MAGE-A2, A3, A6, and C2 were found
to be upregulated in cancer and all bind
to TRIM28, also known as KAP1 or
TIF-1beta. TRIM28 is also overexpressed
in certain cancers, and Potts and
colleagues [6] previously reported
that the MAGEA3/6–TRIM28 complex
induces the degradation of the
tumor suppressor p53. The regulation
of a p53 ortholog by a TRIM28 ortholog
is conserved back to Drosophila and
is likely to play a role in the function of
the MAGE-A3/6 proteins in some
cancers [7]. However, several cell
lines in which MAGE-A2/3 have been
shown to be essential for cell
viability are p53-null, suggesting that
additional targets of TRIM28 in
cancer may exist [5]. Taking advantage
of protein microarrays bearing >9,000
baculovirally produced recombinant
proteins, Potts and colleagues [5] now
demonstrate that AMPKa1 is one of the
most robust substrates degraded by
TRIM28.
Consistent with that finding,
knockdown of MAGE-A3/6 or TRIM28
resulted in a robust increase in total
AMPKa1 and activated phospho-Thr172
AMPKa1. Activation of AMPK via loss of
MAGE-A3/A6 or TRIM28 resulted in
increased phosphorylation of AMPK
substrates like acetyl coenzyme A
carboxylase and ULK1 (Unc51-like kinase
1), as well as expected increases in
autophagy and suppression of
mammalian target of rapamycin (mTOR)urrent Biology 25, R409–R430, May 18, 2015 ª[5]. Rewiring of metabolism towards
an mTOR-dependent, pro-growth,
glycolytic pathway has been observed
with AMPK deficiency in other
settings where AMPK appears to
behave as a classic tumor suppressor
whose loss promotes cancer [8]. Thus,
it appears that the cancer-specific
upregulation of MAGE-A3/A6, and
possibly other MAGE family members,
triggers ubiquitination and degradation
of AMPKa1, promoting tumorigenesis.
This makes the inactivation of
AMPK signaling a common event
shared by LKB1-mutant cancers and
tumors overexpressing MAGE-A3/A6
(Figure 1).
Upon examination of these findings in
human tumor samples, a correlation
between MAGE-A3/A6 mRNA expression
and loss of total and phospho-AMPKa
was observed in colon, breast, and lung
cancers. MAGE-overexpressing cancer
cell lines also displayed heightened
sensitivity to AMPK agonists, which
include direct allosteric activators, like
A769662, in addition to metabolic agents
like AICAR and the widely prescribed
diabetes therapeutic metformin [5].
This indicates that patients with tumors
expressing MAGE-A mRNAs may have
potential therapeutic opportunities with
AMPK agonists.
Interestingly, increased expression of
MAGE-A proteins has also been observed
to play a critical role in specific cancer
contexts. Studies of estrogen receptor
positive (ER+) breast cancers and their
therapeutic response to tamoxifen
revealed that tamoxifen-resistant clones
uniquely upregulate MAGE-A2, and
MAGE-A2 expression alonewas sufficient
to confer resistance to tamoxifen in
multiple models [9].
Further to this new finding of a
cancer-specific gene promoting AMPKa1
ubiquitination and degradation, which
particular E3 ligases promote this process
in normal tissues? Could TRIM28 partner
with other MAGE proteins or other
scaffolds to promote AMPKa1 or
AMPKa2 turnover in non-cancerous
conditions and in the testis? It is notable
that another TRIM protein, TRIM32
(which is not in the same three-member
TIF subfamily of TRIMs as TRIM28), was
previously shown to promote AMPKa1
ubiquitination in vitro, though this effect
appeared non-specific and was not2015 Elsevier Ltd All rights reserved R419
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Figure 1. Cancer cells upregulate E3 ligase complex components to stimulate TRIM28-
dependent degradation of p53 and AMPK.
In normal cells, the tumor suppressors p53 and LKB1 restrict growth. LKB1 does so in part via activating
AMPK to inhibit the mTOR complex 1 (mTORC1) and promote autophagy. In some cancer cells,
the normally testes-specific ubiquitin ligase scaffold proteins MAGE-A3 and -A6 get induced and
now recruit their binding partner, the E3 RING-domain ubiquitin ligase TRIM28, to its substrates
AMPKa1 and p53. This results in the ubiquitin-dependent degradation of both p53 and AMPKa1,
causing loss of autophagy and hyperactivation of mTORC1. In other tumor settings, such as lung
adenocarcinomas, a significant fraction of tumors acquire inactivating mutations in both p53 and LKB1,
functionally mimicking the action of MAGE-A3/A6 upregulation to block those two tumor suppressor
pathways.
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Dispatchesexamined in vivo [10]. This does, however,
raise the possibility that other TRIM family
members may dictate AMPKa turnover
in other settings. It would be particularly
interesting to examine in metabolic
contexts where AMPK activity may
be adaptively downregulated, whether
E3 ligases or E3 ligase adaptors are
transcriptionally induced under
conditions of metabolic excess to
target AMPK or other parts of the
AMPK pathway for degradation.
While the MAGE-A3/6–TRIM28
complex targets AMPKa1, another E3
ubiquitin ligase named WWP1, a member
of the HECT-domain family, was recently
reported to specifically target AMPKa2.
Notably WWP1 was found to degrade
AMPKa2 under high-glucose conditions
when AMPK is known to be functionally
inactive, such as in C2C12 cells in high
glucose or in db/db mouse models of
insulin resistance and obesity-induced
diabetes [11]. Like TRIM28-mediatedR420 Current Biology 25, R409–R430, May 1regulation of p53 and ZNF transcription
factor turnover [12,13], the previously
described targets for WWP1 were
SMADs, KLF family transcription factors
and members of the p53 family [14].
It will be particularly interesting to further
define the contexts in which WWP1 or
other E3 ligases control the rapid
degradation of AMPKa1 and AMPKa2
proteins, and to identify the other
proteins that are co-degraded by these
same E3 ligases. This mechanism of
coordinated rapid turnover of critical
central regulators by a common E3
ligase could be a mechanism for
acute (and adaptive) metabolic
changes. Gaining a more thorough
understanding of which particular E3
ligases mediate AMPK turnover, in
which contexts, and what else is
simultaneously targeted for destruction
may provide novel therapeutic
opportunities for cancer and a host of
other metabolic disorders.8, 2015 ª2015 Elsevier Ltd All rights reservedREFERENCES
1. Hardie, D.G. (2014). AMP-activated protein
kinase: maintaining energy homeostasis at the
cellular and whole-body levels. Annu. Rev.
Nutr. 34, 31–55.
2. Hardie, D.G., and Alessi, D.R. (2013). LKB1
and AMPK and the cancer-metabolism
link - ten years after. BMC Biol. 11, 36.
3. Svensson, R.U., and Shaw, R.J. (2012).
Cancer metabolism: Tumour friend or foe.
Nature 485, 590–591.
4. Hardie, D.G. (2014). AMPK–sensing energy
while talking to other signaling pathways.
Cell Metab. 20, 939–952.
5. Pineda, C.T., Ramanathan, S., Fon Tacer, K.,
Weon, J.L., Potts, M.B., Ou, Y.H., White, M.A.,
and Potts, P.R. (2015). Degradation of AMPK
by a cancer-specific ubiquitin ligase. Cell 160,
715–728.
6. Doyle, J.M., Gao, J., Wang, J., Yang, M., and
Potts, P.R. (2010). MAGE-RING protein
complexes comprise a family of E3 ubiquitin
ligases. Mol. Cell 39, 963–974.
7. Allton, K., Jain, A.K., Herz, H.M., Tsai, W.W.,
Jung, S.Y., Qin, J., Bergmann, A., Johnson,
R.L., and Barton, M.C. (2009). Trim24 targets
endogenous p53 for degradation. Proc. Natl.
Acad. Sci. USA 106, 11612–11616.
8. Faubert, B., Boily, G., Izreig, S., Griss, T.,
Samborska, B., Dong, Z., Dupuy, F.,
Chambers, C., Fuerth, B.J., Viollet, B., et al.
(2013). AMPK is a negative regulator of the
Warburg effect and suppresses tumor growth
in vivo. Cell Metab. 17, 113–124.
9. Wong, P.P., Yeoh, C.C., Ahmad, A.S., Chelala,
C., Gillett, C., Speirs, V., Jones, J.L., and
Hurst, H.C. (2014). Identification of MAGEA
antigens as causal players in the development
of tamoxifen-resistant breast cancer.
Oncogene 33, 4579–4588.
10. Roma-Mateo, C., Moreno, D., Vernia, S.,
Rubio, T., Bridges, T.M., Gentry, M.S., and
Sanz, P. (2011). Lafora disease E3-ubiquitin
ligase malin is related to TRIM32 at both the
phylogenetic and functional level. BMC Evol.
Biol. 11, 225.
11. Lee, J.O., Lee, S.K., Kim, N., Kim, J.H., You,
G.Y., Moon, J.W., Jie, S., Kim, S.J., Lee, Y.W.,
Kang, H.J., et al. (2013). E3 ubiquitin ligase,
WWP1, interacts with AMPKalpha2 and
down-regulates its expression in skeletal
muscle C2C12 cells. J. Biol. Chem. 288,
4673–4680.
12. Espantman, K.C., and O’Shea, C.C. (2010).
aMAGEing new players enter the RING to
promote ubiquitylation. Mol. Cell 39, 835–837.
13. Xiao, T.Z., Suh, Y., and Longley, B.J. (2014).
MAGE proteins regulate KRAB zinc finger
transcription factors and KAP1 E3 ligase
activity. Arch. Biochem. Biophys. 563,
136–144.
14. Chen, C., and Matesic, L.E. (2007). The
Nedd4-like family of E3 ubiquitin ligases and
cancer. Cancer Met. Rev. 26, 587–604.
